MA32471B1 - Composés de borates esters et compositions pharmaceutiques contenant des composés - Google Patents

Composés de borates esters et compositions pharmaceutiques contenant des composés

Info

Publication number
MA32471B1
MA32471B1 MA33514A MA33514A MA32471B1 MA 32471 B1 MA32471 B1 MA 32471B1 MA 33514 A MA33514 A MA 33514A MA 33514 A MA33514 A MA 33514A MA 32471 B1 MA32471 B1 MA 32471B1
Authority
MA
Morocco
Prior art keywords
compounds
pharmaceutical compositions
compositions containing
borate esters
containing compounds
Prior art date
Application number
MA33514A
Other languages
Arabic (ar)
English (en)
Inventor
Eric L Elliott
Abu J Ferdous
Michael J Kaufman
Sonja A Komar
Debra L Mazaik
Quentin J Mccubbin
Phoung M Nguyen
Vaithianathan Palaniappan
Raymond D Skwierczynski
Nobel T Truong
Csanad M Varga
Peter N Zawaneh
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41061278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32471(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA32471B1 publication Critical patent/MA32471B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)

Abstract

La présente invention concerne de nouveaux composés convenant comme inhibiteurs de protéasomes. L'invention concerne également des compositions pharmaceutiques comprenant les composés de l'invention et des procédés d'utilisation de ces compositions pour le traitement de diverses affections.
MA33514A 2008-06-17 2011-01-13 Composés de borates esters et compositions pharmaceutiques contenant des composés MA32471B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13224408P 2008-06-17 2008-06-17
US21149909P 2009-03-31 2009-03-31
PCT/US2009/003602 WO2009154737A1 (fr) 2008-06-17 2009-06-16 Composés de borates esters et compositions pharmaceutiques contenant des composés

Publications (1)

Publication Number Publication Date
MA32471B1 true MA32471B1 (fr) 2011-07-03

Family

ID=41061278

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33514A MA32471B1 (fr) 2008-06-17 2011-01-13 Composés de borates esters et compositions pharmaceutiques contenant des composés

Country Status (39)

Country Link
US (17) US20090325903A1 (fr)
EP (6) EP3536693A1 (fr)
JP (10) JP5566380B2 (fr)
KR (5) KR101691093B1 (fr)
CN (10) CN103435638A (fr)
AR (1) AR072162A1 (fr)
AU (1) AU2009260778B2 (fr)
BR (4) BR122014008750A2 (fr)
CA (2) CA2921946C (fr)
CL (1) CL2010001475A1 (fr)
CO (1) CO6321289A2 (fr)
CR (3) CR11850A (fr)
CY (1) CY1116435T1 (fr)
DK (2) DK2730581T3 (fr)
DO (1) DOP2010000384A (fr)
EA (4) EA201500432A1 (fr)
EC (2) ECSP11010763A (fr)
ES (2) ES2541467T5 (fr)
FI (1) FI2318419T4 (fr)
GE (2) GEP201706703B (fr)
HK (7) HK1198254A1 (fr)
HR (1) HRP20150592T4 (fr)
IL (3) IL210056B (fr)
MA (1) MA32471B1 (fr)
MX (4) MX358222B (fr)
MY (2) MY155592A (fr)
NO (1) NO2017016I1 (fr)
NZ (4) NZ624121A (fr)
PE (5) PE20100256A1 (fr)
PH (3) PH12015501192A1 (fr)
PL (1) PL2318419T3 (fr)
PT (2) PT2318419E (fr)
RS (1) RS54020B2 (fr)
SG (2) SG10201701524XA (fr)
SI (1) SI2318419T2 (fr)
TW (3) TWI542351B (fr)
UA (1) UA115131C2 (fr)
WO (1) WO2009154737A1 (fr)
ZA (4) ZA201009177B (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
JP5734656B2 (ja) 2007-10-04 2015-06-17 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
DK2730581T3 (en) * 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
KR101023994B1 (ko) 2008-08-28 2011-03-28 한국생산기술연구원 디지털 밴드용 커넥터, 리셉터클 및 커넥터 조립체
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (fr) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Utilisation de peptides epoxycetones pour la suppression de la metastase
CA2791651C (fr) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Composes pour inhibition de l'immunoproteasome
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2624818B1 (fr) 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Formulations de bortézomib stabilisées par de l'acide borique
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
EP2723751A1 (fr) 2011-06-22 2014-04-30 Cephalon, Inc. Inhibiteurs du protéasome et leurs méthodes de préparation, de purification et d'utilisation
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013071163A2 (fr) 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarqueurs de la sensibilité vis-à-vis d'inhibiteurs du protéasome
EP2776043B1 (fr) * 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilité à des inhibiteurs du protéasome
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US20160008382A1 (en) * 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
CA2862320A1 (fr) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methode de traitement d'un cancer nasopharynge
CA2866135A1 (fr) * 2012-03-02 2014-09-06 Dr. Reddy's Laboratories Limited Compositions pharmaceutiques comprenant des composes acide boronique
CA2784240C (fr) 2012-03-27 2014-07-08 Innopharma, Inc. Formulations stables a base de bortezomib
WO2014011695A2 (fr) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
ITMI20121394A1 (it) 2012-08-06 2014-02-07 Chemi Spa Esteri di bortezomib e loro formulazioni
WO2014200969A2 (fr) * 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Méthodes de traitement du cancer
JP6165986B2 (ja) * 2013-08-23 2017-07-19 シントン・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂ．Ｖ． ボルテゾミブを含む医薬組成物
CN105705149A (zh) * 2013-10-03 2016-06-22 米伦纽姆医药公司 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法
WO2015117136A1 (fr) * 2014-02-03 2015-08-06 Ohio State Innovation Foundation Esters d'acide boronique et leurs formulations pharmaceutiques
JP2015200016A (ja) * 2014-03-31 2015-11-12 富士フイルム株式会社 水分解用光電極、水分解装置
AU2015264272A1 (en) 2014-05-20 2016-11-24 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
WO2016022955A1 (fr) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
EP3031811A1 (fr) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Esters d'acide malique de bortézomib
MA41505A (fr) * 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CZ2015233A3 (cs) 2015-04-03 2016-10-12 Zentiva, K.S. Způsob přípravy Ixazomib citrátu
CZ2015253A3 (cs) 2015-04-15 2016-10-26 Zentiva, K.S. Nové formy Ixazomib citrátu
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120836A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
EP3120837A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
CA2998830A1 (fr) 2015-09-16 2017-03-23 Mylan Laboratories Limited Polymorphes de citrate d'ixazomib et leurs procedes de preparation
CN106608883A (zh) * 2015-10-21 2017-05-03 北京大学 蛋白酶体抑制剂mln9708的合成方法
EP3370729B1 (fr) 2015-11-04 2023-09-27 Takeda Pharmaceutical Company Limited Méthodes de l'identification, de l'évaluation et du traitement de malades atteints du myélome multiple
CN106986884A (zh) * 2016-01-20 2017-07-28 成都贝斯凯瑞生物科技有限公司 一种高效的高纯度含硼化合物制备方法
CN105622658B (zh) * 2016-03-18 2018-06-19 中国药科大学 非肽类蛋白酶体抑制剂、其药物组合物、制备方法和应用
WO2017163190A1 (fr) * 2016-03-23 2017-09-28 Dr. Reddy’S Laboratories Limited Citrate d'ixazomib amorphe et dispersion solide de celui-ci
CN107224569A (zh) * 2016-03-26 2017-10-03 复旦大学 一种硼替佐米水溶性药用组合物及其制备方法和用途
CZ2016204A3 (cs) 2016-04-08 2017-11-01 Zentiva, K.S. Formulace Ixazomib citrátu formy 3
ES2836050T3 (es) 2016-06-21 2021-06-23 Teva Pharmaceuticals Int Gmbh Formas en estado sólido de citrato de ixazomib
EP3476850B1 (fr) * 2016-07-25 2024-12-11 Shenzhen TargetRx, Inc. Composé d'acide borique substitué, composition pharmaceutique le comprenant et son application
WO2018027022A1 (fr) * 2016-08-04 2018-02-08 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30
TW201831191A (zh) * 2017-01-23 2018-09-01 大陸商成都奥璟生物科技有限公司 一種新的硼酸衍生物及其藥物組合物
ES3036483T3 (en) 2017-02-28 2025-09-19 Mayo Found Medical Education & Res Combinations for use in the treatment of cancer
WO2018158697A1 (fr) 2017-03-03 2018-09-07 Fresenius Kabi Oncology Limited Procédé de préparation de citrate d'ixazomib
WO2018173071A1 (fr) * 2017-03-20 2018-09-27 Msn Laboratories Private Limited, R&D Center Nouvelles formes cristallines de citrate d'ixazomib et son procédé de préparation
CN106916177B (zh) * 2017-03-23 2019-04-23 南京陵瑞医药科技有限公司 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
CN108794520B (zh) * 2017-05-02 2020-07-24 北京大学 包括埃沙佐米在内的硼酸柠檬酸酯类化合物的合成方法
US11414437B2 (en) 2017-07-28 2022-08-16 Chengdu Origin Biotechnology Limited Company Borate compound, and synthesis method therefor and uses thereof
IL272806B2 (en) 2017-08-24 2023-09-01 Merck Patent Gmbh The history of boronic acid, its preparation and pharmaceutical preparations containing it
US20200199159A1 (en) 2017-08-25 2020-06-25 Synthon B.V. Process for making ixazomib or intermediates therefor
WO2019043544A1 (fr) * 2017-09-02 2019-03-07 Sun Pharmaceutical Industries Limited Procédé de préparation de citrate d'ixazomib
CN111108125A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CN113603713B (zh) * 2017-12-05 2024-11-12 深圳市塔吉瑞生物医药有限公司 一种取代的硼酸酯化合物的制备方法及其晶型
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10118937B1 (en) 2018-01-03 2018-11-06 Scinopharm Taiwan, Ltd. Process for preparing ixazomib citrate and intermediates therefor
CN110041353A (zh) * 2018-01-16 2019-07-23 成都译山生物科技有限公司 一种新的硼酸水杨酸酯类衍生物及其药物组合物
KR102656571B1 (ko) 2018-03-05 2024-04-11 아르커스 바이오사이언시즈 인코포레이티드 아르기나아제 억제제
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
CN112469480A (zh) 2018-07-26 2021-03-09 默克专利股份公司 硼酸衍生物
CN115772188A (zh) * 2018-08-02 2023-03-10 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物的硼酸酯
CN115403603A (zh) 2018-09-14 2022-11-29 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
ES3034676T3 (en) 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
CN110357787A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 依沙佐米合成工艺研究
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023232830A1 (fr) 2022-06-02 2023-12-07 Merck Patent Gmbh Produits d'addition d'acide boronique
JP2025521648A (ja) 2022-06-30 2025-07-10 プリンシピア バイオファーマ インコーポレイテッド 環状ボロン酸エステル及びその使用
EP4611798A1 (fr) 2022-11-02 2025-09-10 Celgene Corporation Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur
CN116396312A (zh) * 2022-12-26 2023-07-07 重庆迈德凯医药有限公司 一种枸橼酸艾沙佐米的制备方法
WO2025117822A1 (fr) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Gélification déclenchée par le glucose de nanobobines peptidiques supramoléculaires avec des motifs de liaison au glucose
CN117964650B (zh) * 2024-03-28 2024-06-07 成都硕德药业有限公司 一种枸橼酸伊沙佐米的制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449082A (en) * 1891-03-24 milbeadt
US2160413A (en) 1935-04-16 1939-05-30 Schering Ag Polyiodo derivatives of acylamino acids and their salts and a method of making the same
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
JPS6197352A (ja) * 1984-10-17 1986-05-15 Dai Ichi Kogyo Seiyaku Co Ltd 安定性に優れた組成物
JPS6233170A (ja) 1985-08-07 1987-02-13 Tokuyama Soda Co Ltd 環状ポリエ−テル化合物
JPH0813759B2 (ja) 1986-09-01 1996-02-14 富士写真フイルム株式会社 アルコキシベンゼン誘導体の製造方法
JP2512303B2 (ja) 1987-03-20 1996-07-03 呉羽化学工業株式会社 ２−オキサゾリン−４，５−ジオンのフエニルヒドラゾン誘導体
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (fr) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
US5442100A (en) * 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
ES2098484T3 (es) 1992-08-14 1997-05-01 Procter & Gamble Detergentes liquidos que contienen un acido alfa-amino-boronico.
US5935944A (en) * 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US5492900A (en) * 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
JP3403009B2 (ja) 1996-07-12 2003-05-06 キヤノン株式会社 可動部材の変位と気泡成長を伴う液体吐出方法、該吐出方法に用いられる液体吐出ヘッド、ヘッドカートリッジ及びこれらを用いた液体吐出装置
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
EP0979096B1 (fr) 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Traitement d'infarctus par inhibition de nf-kappab
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
US20010012854A1 (en) 1997-12-16 2001-08-09 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
AU6229699A (en) 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
US6121149A (en) 1999-04-22 2000-09-19 Advanced Micro Devices, Inc. Optimized trench/via profile for damascene filling
KR100307027B1 (ko) 1999-06-17 2001-11-01 서평원 액정 표시장치 및 이것을 이용한 이동 통신 단말기의 표시장치
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
SE0100714D0 (sv) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002145848A (ja) * 2000-11-10 2002-05-22 Kyorin Pharmaceut Co Ltd アルケニルアミノ酸誘導体及びその製造法
EP1217000A1 (fr) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
DK3078667T3 (en) 2001-01-25 2019-01-07 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulation of boric acid compounds
CN100415770C (zh) 2001-05-30 2008-09-03 诺瓦提斯公司 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物
DE10131283A1 (de) 2001-06-28 2003-01-09 Philips Corp Intellectual Pty Phased Array Antenne
WO2003033507A1 (fr) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
JPWO2003033506A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
EP1463719A2 (fr) 2002-01-08 2004-10-06 Eisai Co., Ltd Analogues d'eponemycine et d'epoxomicine et leurs utilisations
WO2003105860A1 (fr) 2002-06-14 2003-12-24 Novo Nordisk A/S Utilisation pharmaceutique d'acides boroniques et de leurs esters
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
EP1396270B1 (fr) 2002-09-09 2006-05-10 Trigen Limited Sels d'acide boronique et leur utilisation dans la préparation de médicaments pour le traitement de la thrombose
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PE20050360A1 (es) * 2003-08-14 2005-06-10 Cephalon Inc Inhibidores del proteasoma
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
NZ598172A (en) * 2004-03-30 2013-08-30 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
ES2510840T3 (es) 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
WO2006008660A2 (fr) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Nouveaux polypeptides purifies derives de streptococcus pneumoniae
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN101120006A (zh) * 2005-02-11 2008-02-06 赛福伦公司 蛋白酶体抑制剂及其使用方法
AU2006242446A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
AU2006264305B2 (en) 2005-07-05 2012-07-05 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
ZA200804679B (en) * 2005-12-08 2010-02-24 Millenium Pharmaceuticals Inc Bicyclic compounds with kinase inhibitory activity
US20090304631A1 (en) 2006-01-27 2009-12-10 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
RU2409570C2 (ru) 2006-02-03 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. Производные триазола
CL2007002499A1 (es) * 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2009006473A2 (fr) 2007-07-05 2009-01-08 Trustees Of Tufts College Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
MY161991A (en) * 2007-08-06 2017-05-31 Millennium Pharm Inc Proteasome inhibitors
ITMI20072397A1 (it) 2007-12-20 2009-06-21 Gambro Lundia Ab Apparecchiatura medicale per il trattamento extracorporeo
DK2730581T3 (en) * 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012148336A1 (fr) 2011-04-29 2012-11-01 Telefonaktiebolaget L M Ericsson (Publ) Commande décentralisée de réduction de brouillage dans un système de communication sans fil
JP5724951B2 (ja) 2012-06-11 2015-05-27 日立金属株式会社 ネットワーク管理装置
JP6357023B2 (ja) 2014-06-06 2018-07-11 任天堂株式会社 情報処理プログラム、情報処理装置、情報処理装置の制御方法および情報処理システム

Also Published As

Publication number Publication date
EP2730579A1 (fr) 2014-05-14
SG194349A1 (en) 2013-11-29
US20210198289A1 (en) 2021-07-01
EA027346B1 (ru) 2017-07-31
ES2585114T3 (es) 2016-10-03
ECSP14010763A (es) 2014-07-31
HK1198254A1 (en) 2015-03-20
MY155592A (en) 2015-11-13
EP2318419B1 (fr) 2015-04-08
EP2318419A1 (fr) 2011-05-11
KR101691093B1 (ko) 2016-12-29
EP3536693A1 (fr) 2019-09-11
CR11850A (es) 2011-03-14
US20190263839A1 (en) 2019-08-29
HK1244809A1 (zh) 2018-08-17
DK2318419T4 (da) 2024-12-02
MX358222B (es) 2018-08-10
EP2730581B1 (fr) 2016-04-27
US20190152997A1 (en) 2019-05-23
CR20160014A (es) 2016-02-08
ZA201109368B (en) 2013-10-30
US8859504B2 (en) 2014-10-14
US20200002361A1 (en) 2020-01-02
PH12015501192B1 (en) 2016-01-11
US20150307523A9 (en) 2015-10-29
KR101704694B1 (ko) 2017-02-08
PE20141076A1 (es) 2014-09-05
KR20170068599A (ko) 2017-06-19
PE20141064A1 (es) 2014-09-05
US20140343314A1 (en) 2014-11-20
TWI498333B (zh) 2015-09-01
CN103467565A (zh) 2013-12-25
ES2541467T3 (es) 2015-07-20
TWI543985B (zh) 2016-08-01
AU2009260778A1 (en) 2009-12-23
JP6110813B2 (ja) 2017-04-05
PE20141065A1 (es) 2014-09-05
EA201500432A1 (ru) 2015-11-30
FI2318419T4 (fi) 2025-01-29
CN107253966A (zh) 2017-10-17
CN103435638A (zh) 2013-12-11
BRPI0915300B1 (pt) 2020-06-23
NZ603236A (en) 2014-05-30
AR072162A1 (es) 2010-08-11
NZ624122A (en) 2015-11-27
HK1198252A1 (en) 2015-03-20
KR101690571B1 (ko) 2016-12-28
NZ624123A (en) 2015-11-27
CA2727862C (fr) 2016-04-19
SI2318419T1 (sl) 2015-07-31
RS54020B2 (sr) 2025-05-30
JP2017214396A (ja) 2017-12-07
JP5566380B2 (ja) 2014-08-06
CL2010001475A1 (es) 2011-03-11
MY171021A (en) 2019-09-23
KR20110043599A (ko) 2011-04-27
CN107266480A (zh) 2017-10-20
EA030685B1 (ru) 2018-09-28
PH12015501193A1 (en) 2016-01-11
US10604538B2 (en) 2020-03-31
CA2921946C (fr) 2019-01-08
CN103497210A (zh) 2014-01-08
EP2730581A1 (fr) 2014-05-14
US20220009948A1 (en) 2022-01-13
US20200392164A1 (en) 2020-12-17
CN102066386A (zh) 2011-05-18
ZA201504133B (en) 2016-11-30
JP2025172854A (ja) 2025-11-26
KR101741142B1 (ko) 2017-05-29
ES2541467T5 (en) 2025-03-31
HK1157786A1 (en) 2012-07-06
US20140349966A1 (en) 2014-11-27
ECSP11010763A (es) 2011-02-28
JP5926319B2 (ja) 2016-05-25
JP2014196310A (ja) 2014-10-16
BRPI0915300C1 (pt) 2021-05-25
CN107266482A (zh) 2017-10-20
TW201433317A (zh) 2014-09-01
US20140018301A9 (en) 2014-01-16
CN103497232A (zh) 2014-01-08
US20160031913A1 (en) 2016-02-04
NZ624121A (en) 2015-11-27
BRPI0915300A2 (pt) 2015-10-27
JP2011524903A (ja) 2011-09-08
BR122014008753A2 (pt) 2015-12-29
BR122014008754A2 (pt) 2015-11-03
CY1116435T1 (el) 2017-02-08
PL2318419T3 (pl) 2015-08-31
US20130165390A1 (en) 2013-06-27
JP2014169317A (ja) 2014-09-18
PE20141078A1 (es) 2014-09-05
US20230265111A1 (en) 2023-08-24
MX340186B (es) 2016-06-29
JP2014169316A (ja) 2014-09-18
TWI542351B (zh) 2016-07-21
IL234286A (en) 2017-03-30
EA201500430A1 (ru) 2015-11-30
HK1199260A1 (en) 2015-06-26
BR122014008750A2 (pt) 2015-11-03
US10526351B2 (en) 2020-01-07
GEP201706703B (en) 2017-07-25
CA2921946A1 (fr) 2009-12-23
KR101860743B1 (ko) 2018-05-24
DK2730581T3 (en) 2016-08-15
HRP20150592T1 (hr) 2015-07-03
TW201433569A (zh) 2014-09-01
AU2009260778B2 (en) 2014-08-28
JP2020055829A (ja) 2020-04-09
PE20100256A1 (es) 2010-04-14
CR20160015A (es) 2016-03-09
EA201500431A1 (ru) 2015-11-30
KR20140107483A (ko) 2014-09-04
IL210056A0 (en) 2011-02-28
EA201170036A1 (ru) 2011-06-30
JP2023158150A (ja) 2023-10-26
JP6010066B2 (ja) 2016-10-19
US9175018B2 (en) 2015-11-03
EP2730580A1 (fr) 2014-05-14
US9175017B2 (en) 2015-11-03
SI2318419T2 (sl) 2025-10-30
HK1244827A1 (zh) 2018-08-17
JP2014144981A (ja) 2014-08-14
ZA201009177B (en) 2012-03-28
US11485746B2 (en) 2022-11-01
IL234285B (en) 2018-04-30
IL210056B (en) 2018-04-30
RS54020B1 (sr) 2015-10-30
US20180002350A1 (en) 2018-01-04
BRPI0915300B8 (pt) 2020-07-07
EP2733147A1 (fr) 2014-05-21
MX2010013642A (es) 2010-12-21
US20090325903A1 (en) 2009-12-31
HK1244810A1 (zh) 2018-08-17
PH12015501191A1 (en) 2016-01-11
US20200181176A1 (en) 2020-06-11
MX349769B (es) 2017-08-11
US20200247829A1 (en) 2020-08-06
DK2318419T3 (en) 2015-06-29
SG10201701524XA (en) 2017-04-27
HRP20150592T4 (hr) 2025-02-14
WO2009154737A1 (fr) 2009-12-23
GEP20135847B (en) 2013-06-10
HK1244811A1 (zh) 2018-08-17
CA2727862A1 (fr) 2009-12-23
DOP2010000384A (es) 2011-01-15
PH12015501192A1 (en) 2016-01-11
ZA201304728B (en) 2016-01-27
CN107253975B (zh) 2025-11-04
CN107253975A (zh) 2017-10-17
NO2017016I1 (no) 2017-05-04
KR20140107482A (ko) 2014-09-04
JP2021165288A (ja) 2021-10-14
PH12015501191B1 (en) 2018-10-24
TW201002727A (en) 2010-01-16
US20190048028A1 (en) 2019-02-14
CN103450241A (zh) 2013-12-18
UA115131C2 (uk) 2017-09-25
US20180208609A1 (en) 2018-07-26
CO6321289A2 (es) 2011-09-20
HK1198253A1 (en) 2015-03-20
PT2318419E (pt) 2015-08-25
EP2318419B2 (fr) 2024-10-30
PT2730581T (pt) 2016-08-17
KR20140094663A (ko) 2014-07-30

Similar Documents

Publication Publication Date Title
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA33349B1 (fr) Compositions pharmaceutiques solides et procedes pour leur production
MA30762B1 (fr) Anticorps specifiques du prlr et leurs utilisations
MA35576B1 (fr) Nouveaux composés
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
TN2009000028A1 (fr) Agonistes de ep2
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
TN2014000195A1 (fr) 2-thiopyrimidinones
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
TNSN08428A1 (fr) NOUVELLE FORME d'ADMINISTRATION DU RACECADOTRIL
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires